Abstract Proteins from buckwheat (Fagopyrum esculentum) are strong allergens that can cause serious symptoms, including anaphylaxis, in patients with hypersensitivity. In this study, we successfully developed a modified lactic acid bacterial vector (pNSH) and a recombinant strain of Lactococcus lactis NZ9000 (NZ9000) that produced a major allergenic storage protein of buckwheat, Fagag1 (61.2 kDa, GenBank accession number AF152003), with or without a green fluorescent protein (GFP) tag. GFP fluorescence allows for rapid, simple, and accurate measurement of target protein expression by microscopy or fluorimetry. We describe a convenient method for production of rGFP-Fagag1 fusion and rFagag1 proteins with a good yield in an advantageous probiotic host. We found that in vitro treatment of splenocytes isolated from buckwheat crude protein-immunized mice with rFagag1 increased the expression of allergic inflammation cytokines such as IL-4, IL-13, and IL-17 F. Because it was less antigenic, rGFP-Fagag1 protein from NZ9000 might be of limited use; however, rFagag1 from NZ9000 evoked a robust response as measured by induction of IL-4 and IL-17 F expression levels. The observed allergic activity is indicative of a Th2 cell-mediated immune response and is similar to the effects induced by exposure to buckwheat crude protein. Our results suggest that expression of rFagag1 in NZ9000 may facilitate in vivo applications of this system aimed at improving the specificity of immunological responses to buckwheat allergens.
Introduction
Buckwheat (Fagopyrum esculentum) belongs to the Polygonaceae family of plants and its seeds can be used as food material. Buckwheat is a pseudocereal, that is, buckwheat is a eudicot with seed qualities and uses similar to those of monocot cereals (family Poaceae). Buckwheat can be cultivated under less favorable conditions than rice, including at high altitudes, and it is sometimes used as a substitute for common cereals. Buckwheat is consumed around the world as a health food (Sedej et al. 2012) . In Japan, buckwheat is called "soba" and is consumed mainly in the form of noodles and dumplings. In Western countries, buckwheat is also used in batter for cakes, pancakes, or crepes, and there is growing interest in buckwheat as a health food and as a substitute for wheat flour for gluten-allergic persons (Panda et al. 2010) .
Buckwheat is considered a true food allergen, also classified as a class I food allergen, comparable to the major milk allergen (Ruiter et al. 2006) , the fish allergen parvalbumin (Swoboda et al. 2002) , major peanut allergens (Palmer and Burks 2006) , and the major shrimp allergen (Reese et al. 2005) . Indeed, in affected people, buckwheat consumption can induce severe and even life-threatening anaphylactic reactions. To date, many cases of buckwheat allergies have been reported (De Maat-Bleeker and Stapel 1998; Yoshioka et al. 2004) . Buckwheat allergens induce immunoglobulin Emediated allergies in the gastrointestinal system, skin, and respiratory track and can evoke severe reactions, such as anaphylaxis (Varga et al. 2011; Heffler et al. 2011) . A system for the delivery of buckwheat allergen via mucosal immunization has not previously been developed. However, we speculate that such a system would aid in the study and modulation of T helper type 2 (Th2) cell immune responses.
In this study, we focused on a major allergenic storage protein from buckwheat, Fagag1. A Fagag1 sequence was identified based on NCBI Genbank accession number AF152003. This Fagag1 sequence has high identity to two cDNA clones isolated from a buckwheat cDNA library of developing seeds (defined as "buckwheat mRNA for legumin-like protein, complete cds" at NCBI; Accession numbers D87980 and D87982). Minor differences in sequence length and deduced amino acid sequences among these sequences may be due to isolation of different isoforms from different sources, or could be variety dependent.
Current evidence suggests that probiotic bacteria can play a beneficial role in the prevention or treatment of Th2-biased allergic responses (Kitazawa et al. 2008; Iemoli et al. 2012; Ou et al. 2011) . Lactococcus lactis is a highly efficient probiotic microorganism with a wide range of benefits for human health (Kitazawa et al. 2008) . Experimental data and genomic analyses indicate that L. lactis naturally secretes only a few proteins (Poquet et al. 1998) , and a plasmid-free L. lactis strain does not produce the extra cytoplasmic protease PrtP (Gasson 1983) . These features have drawn the attention of researchers to the potential use of L. lactis for the secretion of biotechnologically important proteins. The nisin-controlled gene expression (NICE) system has become a widely used tool for regulated gene expression in Gram-positive bacteria (Bryan et al. 2000) , including lactic acid bacteria such as L. lactis. The use of the NICE system in lactic acid bacteria might provide a good approach for generating a novel topical antigen delivery vehicle for mucosal immunization (Mercenier et al. 2000) , for example for buckwheat proteins. However, there are no previous reports of such a buckwheat protein expression system in lactic acid bacteria.
Here, we engineered a L. lactis NZ9000 (NZ9000) recombinant strain that produces green fluorescent protein (GFP) fused to Fagag1 (rGFP-Fagag1). The GFP fluorescence signal allows for rapid, simple, and accurate measurement of target protein expression. The aim of the present study was to design a high-level expression system for recombinant Fagag1 and a purification method based on GFP fluorescence that can be used for both small-and large-scale cultures. Development of such a system should facilitate the investigation of the immunological activity of splenocytes isolated from mice immunized with buckwheat crude protein and subsequently treated with rFagag1 or rGFP-Fagag1.
Materials and methods
Bacterial strain and growth conditions NZ9000 is a standard host strain for the NICE system (MoBiTec, Goettingen, Germany). NZ9000 is derived from L. lactis subsp. cremoris MG1363 (MG1363) and contains the regulatory genes nisR and nisK integrated into the pepN gene. NZ9000 was grown in M17 medium supplemented with 0.5 % glucose at 30°C, and gene expression was induced with nisin, as described previously . Plasmid maintenance was ensured by growing recombinant NZ9000 strains in medium supplemented with 20 μg/mL chloramphenicol.
Construction of a recombinant NZ9000 strain
The pNSH vector is a modified form of the L. lactis expression vector pNZ8148 (MoBiTec) and contains the PnisA promoter and a terminator sequence upstream and downstream, respectively, of a multicloning site (MCS). A 6× His tag and factor Xa recognition site are positioned between the PnisA promoter and MCS (Fig. 1a) . The GFP (accession number: AB758275, http://getentry.ddbj.nig.ac.jp/getentry/ ddbj/AB758275?filetype0html), Fagag1 (accession number: AB758276, http://getentry.ddbj.nig.ac.jp/getentry/ddbj/ AB758276?filetype0html), and GFP-Fagag1 coding sequences were optimized for MG1363 codon usage to increase expression levels in NZ9000. The codon-optimized GFP and Fagag1 genes were synthesized by Operon Biotechnologies (Tokyo, Japan) and subcloned into pCR2.1 (Invitrogen, Carlsbad, CA, USA). The resulting plasmid was digested with BamHI and HindIII to excise the GFP, Fagag1, or GFPFagag1 gene cassette, which was then cloned into pNSH vector. The resulting plasmid (pNSH-GFP, pNSH-Fagag1, or pNSH-GFP-Fagag1) contained the GFP, Fagag1, or GFPFagag1 gene cassette under control of the nisin-inducible PnisA promoter (Fig. 1b-d) . The plasmids were introduced in NZ9000 by electroporation using a Gene Pulser Xcell electroporation system (Bio-Rad Laboratories, Inc., CA, USA) following the manufacturer's instructions. The resulting NZ9000 recombinant strains were named NZ9000-GFP, NZ9000-Fagag1, and NZ9000-GFP-Fagag1. NZ9000 was also electroporated with the empty plasmid pNSH to generate a NZ9000 vector control strain (NZ9000-VC).
Small-scale expression of recombinant protein Fresh medium was inoculated 1:20 (v/v) with an overnight culture and incubated statically at 30°C. To induce expression of the recombinant genes, strains were grown to an OD 600 of 0.4, followed by induction with 100 ng/mL nisin for 3 h. To evaluate recombinant protein expression in NZ9000, preparation of cell fractions was performed based on the method described by Le Loir et al. (1998) . Briefly, 2 mL of NZ9000 cultures at a given OD 600 was harvested by 5 min centrifugation at 4°C and 3,000×g. Next, the supernatant was removed; the cell pellet was washed once with 1 mL of TES (10 mM Tris-HCl [pH 8.0], 1 mM EDTA, 25 % sucrose); and the pellet was then resuspended in 70 μL/OD 600 01 of TES containing lysozyme (1 mg/mL). After 30 min of incubation at 37°C, cells (30 μL/OD 600 01) were lysed with 20 % SDS. For electrophoretic separation, equal volumes of 2× sample buffer were added to each sample and the samples were then boiled for 5 min.
The boiled samples were separated by 10 % SDS-PAGE and then transferred onto PVDF membranes. Western blotting was performed with primary antibodies (Abs) against the 6× His tag (BioLegend, Inc., San Diego, CA, USA), followed by incubation with HRP-conjugated secondary Abs (Sigma, St. Louis, MO, USA). Signals were visualized by treating the membranes with TMB peroxidase substrate.
Large-scale expression and purification of recombinant protein
Optimal parameters for rFagag1 and rGFP-Fagag1 expression were assessed by growth curves (OD 600 ), external pH, and when appropriate, GFP fluorescence signal, following induction with various nisin concentrations and incubation for various times (hour). After induction with nisin, a cell pellet obtained by centrifugation was broken by grinding with aluminum oxide powder (3 g per 1 g of cells; Wako, Osaka, Japan) for 15 min, followed by suspension of the broken cells in a standard buffer containing a protease inhibitor cocktail (Sigma). Protein content was measured using a bicinchoninic acid protein assay (Pierce, Rockford, IL, USA). Fluorescence, reported in relative fluorescence units (RFU), was measured using a Fluoroskan Ascent FL Microplate Fluorometer (Thermo Scientific, Tokyo, Japan) by excitation at 485 nm and detection of emission at 538 nm.
The rGFP, rFagag1, and rGFP-Fagag1 proteins were purified using a HisTrap HP column (1 mL, pre-charged with Ni 2+ ; GE Healthcare Japan, Tokyo, Japan) under native conditions, according to the manufacturer's instructions. The flow-through fractions were collected by washing the column with 20 mM imidazole phosphate buffer (pH 8.0). The absorbed factions were eluted using 31.25, 62.5, 125, 250, and 500 mM imidazole phosphate buffer (pH 8.0). After dialysis, the eluted fractions were freeze-dried and analyzed by SDS-PAGE and Western blotting.
Buckwheat crude protein-immunized mice
Pathogen-free female BALB/c mice (4 weeks of age) were purchased from Japan SLC (Shizuoka, Japan) and housed under temperature-and light-controlled conditions. Mice were fed a standard diet of Labo MR Breeder (Nihon Nosan Co., Kanagawa, Japan) and sterile water ad libitum. After a preliminary breeding period of 2 weeks, BALB/c mice (6 weeks of age, n03) were intraperitoneally (i.p.) sensitized once weekly for 3 weeks with 100 μg of buckwheat (Fagopyrum esculentum) crude protein in lyophilized form (GREER Laboratories Inc., Lenoir, NC, USA) and alum (allergen/adjuvant ratio of 1/50). All experimental procedures were conducted in accordance with the Regulations for Animal Experimentation of Shinshu University.
Immunoreactivity assay
The levels of immunoreactivity of rFagag1 and rGFPFagag1 were assessed by real-time quantitative PCR (qPCR), which was used to detect cytokine mRNA expression induced by rFagag1 or rGFP-Fagag1 in splenocytes isolated from buckwheat crude protein-immunized mice. Splenocytes were prepared using standard methods (Shimosato et al. 2009; Ito et al. 2012 ) and were then cultured in a medium at a final concentration of 2×10 6 cells per well (total volume, 1 mL per well). Splenocytes were stimulated with 10 μg/mL purified rFagag1, rGFP-Fagag1, or various concentrations of buckwheat crude protein as a control for 72 h, harvested, and then monitored for cytokine mRNA expression by qPCR as previously described (Shimosato et al. 2009; Shigemori et al. 2012) . Fluorescent qPCR reactions were performed using SYBR Premix Ex Taq (Takara Bio Inc.) and specific primers, with each reaction containing 5 ng of cDNA in a total volume of 25 μL. The β-actin and cytokine primers were purchased from Takara Bio Inc. The PCR cycling conditions were 10 s at 95°C, followed by 45 cycles of 5 s at 95°C, and 30 s at 60°C. As a control, poly (A) + RNA samples were used as templates to check for the presence of contaminating genomic DNA. The sensitivity of the reaction and amplification of contaminant products, such as the extension of self-annealed primers, were evaluated by amplification from various serial dilutions of the cDNA template. For cross-sample comparison of results obtained following various treatments, cytokine mRNA levels were first normalized to mRNA levels obtained for β-actin. The results represent the means ± SD of three independent experiments.
Statistical analysis
All results represent the average of three separate experiments. Statistical analyses were performed using the Bonferroni multiple comparison tests for one-way analysis of variance (ANOVA). Differences were considered significant when P values were less than 0.05.
Results

Construction of recombinant strains at a small scale
We first modified the vector pNZ8148 to generate a vector for inducible expression of tagged proteins, which we call pNSH. The pNSH vector contains an N-terminal 6× His tag, a factor Xa recognition site for cleavage of the 6× His tag, and a multiple cloning site (MCS) between a nisin-inducible promoter and a terminator sequence (Fig. 1a) . Full-length GFP, Fagag1, or both were isolated by restriction enzyme digest and cloned into pNSH, resulting in pNSH-GFP, pNSH-Fagag1, and pNSH-GFP-Fagag1 (Fig. 1a-d) . The plasmids were then electroporated into L. lactis NZ9000. To confirm expression of the recombinant proteins in NZ9000, we next analyzed protein fractions and whole cells from the transfected NZ9000 strains. Following nisinmediated induction, total cellular protein was separated by SDS-PAGE and visualized with Coomassie brilliant blue (CBB), then assayed for the presence of the 6× His tag proteins via Western blotting (Fig. 2a, b) . We monitored the recombinant proteins by staining SDS-PAGE gels with CBB (Fig. 2a) . However, the detection of rGFP, rFagag1, and rGFP-Fagag1 was difficult in CBB-stained gels due to the weak signal of recombinant proteins (Fig. 2a) . In an empty vector control or in the absence of nisin induction, recombinant proteins could not be detected in the NZ9000 strains (Fig. 2b) . Following nisin-induced expression, however, bands corresponding to rGFP (30.6 kDa), rFagag1 (65.4 kDa), and rGFP-Fagag1 (91.7 kDa) were detected in cell fractions from nisin-induced NZ9000-GFP, NZ9000-Fagag1, and NZ9000-GFP-Fagag1, respectively (Fig. 2b) . To confirm expression of rGFP, we next observed cells under visible light ( Fig. 3; light) and by confocal laser microscopy ( Fig. 3; laser) following 3 h of treatment with nisin. As shown in the merged images ( Fig. 3; merge) , NZ9000-GFP and NZ9000-GFP-Fagag1 cells clearly express fluorescence recombinant proteins (Fig. 3) . Based on the results of Western blotting and confocal laser microscopy, we concluded that we successfully induced expression of His-tagged and GFP-fused Fagag1 recombinant proteins using NZ9000 transformed with the pNSH vector containing the GFP, Fagag1, and GFPFagag1 gene cassette.
Establishing optimal conditions for recombinant protein expression and purification
We used GFP fluorescence as an indicator of protein expression following nisin-induced expression of GFP-Fagag1 in NZ9000-GFP-Fagag1. To optimize induction, we assayed GFP intensity following treatment with various concentrations of nisin for various times in large-scale cultures (i.e., 50 mL). When NZ9000-GFP-Fagag1 cells were stimulated with 62.5-500 ng/mL nisin, the resulting cell fractions had significant high levels of fluorescence compared with cell fractions from NZ9000-VC (Fig. 4a) . Thus, we determined that a nisin concentration of 100 ng/mL was optimal for inducing expression of the recombinant protein, as indicated by the highest levels of fluorescence observed at this concentration. The maximum detectable GFP fluorescence was observed 1-3 h after induction (Fig. 4b) . Notably, in cell cultures treated with 100 ng/mL nisin, the external pH of the medium dropped from 6.5 to 5.0 (Fig. 4c) , and the stationary phase was reached 4 h after induction (Fig. 4d) . We next used these optimal conditions in very large-scale cultures (i.e., 3 L) in an effort to generate and isolate significant quantities of the recombinant proteins. To do this, NZ9000-GFP, NZ9000-Fagag1, and NZ9000-GFP-Fagag1 were induced by nisin in 3 L large-scale culture, and rGFP, rFagag1, and rGFP-Fagag1 were purified using HisTrap HP column. To confirm the purification of each recombinant protein, we analyzed the crude lysate before purification, column flow-through, and eluted fractions by SDS-PAGE and Western blotting with anti-6× His-tag Ab (Fig. 5a-c) . A corresponding band with rGFP ( Fig. 5a ), rFagag1 (Fig. 5b) , or rGFP-Fagag1 (Fig. 5c ) was observed in each eluted fraction. The fraction eluted with 62.5 mM imidazole in particular was enriched for the recombinant proteins. Because endotoxin could interfere with the subsequent use of purified proteins, we tested the recombinant protein-positive fractions for endotoxin activity and found that endotoxin could not be detected.
Immunological activity of the purified rFagag1 and rGFP-Fagag1
To determine if purified rFagag1 and rGFP-Fagag1 have immunological activity, splenocytes from buckwheat crude protein-immunized mice were stimulated with buckwheat crude protein or purified recombinant proteins in vitro. We Nisin-induced NZ9000 cells were analyzed under visible and fluorescent light, and then merged images were generated. Bar05 μm used buckwheat crude protein to determine the optimal amount of allergen (Fig. 6a) . Buckwheat crude protein was capable of inducing high levels of expression of IL-13 mRNA in splenocytes at a concentration of >10 μg/mL buckwheat. We next examined the ability of purified rFagag1 and rGFPFagag1 to induce IL-13 mRNA expression in splenocytes isolated from buckwheat-immunized mice. In splenocytes stimulated with 10 μg/mL rFagag1 for 72 h, expression of IL-13 mRNA was significantly higher than what was observed for a negative control (medium) or 10 μg/mL rGFP-Fagag1 (Fig. 6b) . The rGFP-Fagag1 treatment induced a small but significant level of up-regulation of IL-13 mRNA as compared with the control (Fig. 6b) . We next evaluated the ability of rFagag1 to induce the Th2 and Th17 cytokines. Induction of IL-4 and IL-17 F facilitates the establishment of Th2 and Th17-based adaptive immune responses. Thus, we examined the ability of rFagag1 to induce IL-4 (Fig. 7a) and IL-17 F (Fig. 7b ) mRNA in splenocytes from buckwheat-immunized mice by real-time qPCR. The cells were cultured as described above with rFagag1 for 72 h. Our preliminary data indicate that rGFP does not induce IL-4 and IL-17 F mRNA expression (data not shown). Expression of IL-4 and IL-17 F was elevated in rFagag1-treated splenocytes from buckwheat-immunized mice; however, treatment of splenocytes with buckwheat protein resulted in higher levels of IL-4 and IL-17 F than were induced by rFagag1 (Fig. 7) .
Discussion
Expression and purification of recombinant fusion proteins is a well-accepted approach for production of allergen proteins. Previously, we generated a recombinant NZ9000 strain expressing a GFP fusion with α S1 casein, a milk major allergen . In this study, maximal expression of a GFP-Fagag1 fusion in NZ9000-GFP-Fagag1 cells grown at 30°C was achieved with the following culture parameters: OD 600 of 0.4, induction with 100ng/mL nisin, and 1-3 h of incubation. Fluorescence is a convenient way to evaluate protein expression and purification (Niu et al. 2008; Waldo et al. 1999) . To take advantage of this, we constructed a GFP fusion expression vector that can be propagated in NZ9000. Based on the results with His-tagged GFP, the vector appears to be generally applicable for the expression of GFP fusion proteins, including GFP-Fagag1. As there was a good correlation between RFU and the amount of rGFP-Fagag1 (data not shown), we were able to optimize expression levels by simply measuring GFP RFU. To test the potential immunological activity of rGFP-Fagag1, we asked if purified rGFP-Fagag1 could induce Th2-mediated allergic responses in splenocytes isolated from buckwheat-immunized mice. Th2 cell-mediated immune responses against "innocuous" antigens play a role in triggering allergic diseases (Romagnani 2004) and are characterized by the prevalent production of IL-4, IL-5, IL-9, and IL-13 (Nguyen and Casale 2011) . Here, we showed that splenocytes isolated from buckwheat crude protein-immunized mice and subsequently treated with purified rGFP-Fagag1 for 72 h did not induce IL-13 mRNA to high levels. Thus, although it induced a modest response, purified rGFP-Fagag1 purified from NZ9000 is unlikely to be useful for studies specifically focused on food-based allergic responses. Our studies using purified rFagag1 show more promise. Treatment with rFagag1 up-regulated the expression of IL-4, IL-13, and IL-17 F in splenocytes from buckwheatimmunized mice, although not to the same extent that we observed with buckwheat crude protein. The identification of novel helper T (Th) cell subsets, i.e., IL-17-producing Th cells (Th17 cells) and regulatory T cells (Treg cells), provides new insight into understanding the molecular mechanisms involved in the development of infectious and autoimmune diseases, as well as immune responses, and thus leads to a revision of the classic Th1/Th2 paradigm (Cosmi et al. 2011 ). Th17 cells may also contribute to the pathogenesis of classically recognized Th2-mediated allergic disorders. IL-17 F, which like IL-17 is a member of the IL-17 cytokine family of molecules, binds to IL-17R and has similar pathological activities as compared with IL-17 (Suzuki et al. 2007; Vazquez-Tello et al. 2012) . IL-17 F is derived from a limited set of cell types, including activated CD4 + T cells, basophils, and mast cells. Moreover, IL-17 F induces expression of several CXC chemokines and cytokines, including profibrotic cytokines such as IL-6 and TGF-β (Fujie et al. 2012; TakeiTaniguchi et al. 2012; Vazquez-Tello et al. 2012) . In a mouse model with increased numbers of neutrophils in the airways, over-expression of IL-17 F was shown to have an additive effect on antigen-induced allergic inflammatory responses, such as increased airway hyper-responsiveness, goblet cell hyperplasia, and mucin gene expression, phenotypes that are associated with the pathophysiology of allergic inflammation (Hurst et al. 2002; Oda et al. 2005) . The symptoms of buckwheat allergies are dependent on how buckwheat is used in a product (i.e., the mode of delivery). Buckwheat products that are ingested induce food allergy-associated symptoms, whereas products such as pillows stuffed with buckwheat chaff can cause nocturnal asthma. The most dangerous allergic reaction to buckwheat is anaphylaxis, which can lead to a fatal shock if left untreated. Importantly, then, understanding the cellular source and targeting cells of the IL-17 cytokine family may provide a basis for elucidating cellular mechanisms that underlie allergic inflammation and improve therapeutic approaches to buckwheat allergies. The immunogenicity of soluble proteins administered orally or intranasally is generally low and can be significantly enhanced either by coupling the protein to a bacterial carrier or by genetic engineering bacteria to produce the target antigen. Food grade or commensal Gram-positive bacteria constitute an attractive alternative to attenuated pathogenic bacteria for inducing immunity (Wells and Mercenier 2008) . More specifically, lactic acid bacteria are an attractive alternative to attenuated pathogens, as they can be good candidates for the development of novel oral vectors for mucosal delivery strategies. Today, sufficient data are available supporting the idea that lactic acid bacteria, notably lactococci and lactobacilli, are excellent candidates as delivery vectors of therapeutic proteins and thus should be useful in the development of novel preventive and therapeutic strategies. L. lactis and certain species of lactobacilli possess a number of attractive properties that make them suitable candidates for the development of mucosal vaccines (Mannam et al. 2004 ).
In conclusion, we have described a convenient method for the production of rFagag1 or rGFP-fused Fagag1 with a good protein yield in an advantageous probiotic host. We have demonstrated an assay of immunological activity for rFagag1 in which the recombinant protein shows a high level of allergic activity, including up-regulation of IL-17 F expression. rFagag1 purified from NZ9000 might also be useful for significant applications in basic research into food allergic disease. In addition, the strain NZ9000-Fagag1 may be a useful candidate organism for the development of allergic vaccines, particularly oral vaccines. However, the future application of prophylactic and therapeutic strategies based on NZ9000-Fagag1 first requires the completion of a number of studies, including a clear demonstration of efficacy in in vivo trials.
